More on CAPR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $8.10 |
|
|||
| Open | $8.10 | ||||
| 52 Wk High | $5.40 | ||||
| 52 Wk Low | $1.88 | ||||
| Day High | $8.10 | ||||
| Day Low | $8.10 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 9,849 | ||||
- Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
- Caprock Provides 2026 Operational Highlights and an Update on its 2027 Work Program at Destiny
- Capricor's DMD drug slows upper limb decline in 24-month study
- Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
- Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR) Ahead of Presentaion
- Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
- Form SCHEDULE 13G CAPRICOR THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC
- B.Riley Upgrades Capricor Therapeutics (CAPR) to Buy
- Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
- Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
Entities mentioned with CAPR
- FDA | View Related Stories »
- Twitter | View Related Stories »
- S3 | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
